Regenxbio

Yahoo Finance • 3 days ago

Regenxbio files $300M mixed shelf offering

[Shares Certificate] Bluberries * Regenxbio (RGNX [https://seekingalpha.com/symbol/RGNX]) has filed a shelf registration to offer up to $300M in securities. * The offering [https://seekingalpha.com/filing/58350086] may include common... Full story

Yahoo Finance • 24 days ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial open and enrolling New 12-month analy... Full story

Yahoo Finance • 2 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

ROCKVILLE, Md., Oct. 9, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-... Full story

Yahoo Finance • 2 months ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 2 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Over 1,200 participants enrolled in ATMOSPHERE® and ASCENT® pivotal trials, representing largest global gene therapy program ever conducted Subretinal surabgene lomparvovec on track to be first gene therapy for wet AMD Topline pivotal data... Full story

Yahoo Finance • 3 months ago

REGENXBIO Reports Positive Data From Phase I/II/III CAMPSIITE Trial Of RGX-121

(RTTNews) - REGENXBIO Inc. (RGNX) announced positive data from the Phase I/II/III CAMPSIITE trial of clemidsogene lanparvovec or RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II, also known as Hunter syndrome. Prima... Full story

Yahoo Finance • 4 months ago

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • 4 months ago

REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls

REGENXBIO INC (NASDAQ:RGNX [https://www.chartmill.com/stock/quote/RGNX]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company posted revenue of $21.36 mi... Full story

Yahoo Finance • 4 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidance Clemidsogene lanparvovec (RGX-12... Full story

Yahoo Finance • 4 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiated New Phase II ALTITUDE® trial data demonstrate a durable safety and efficacy profile observed through two years wit... Full story

Yahoo Finance • 4 months ago

Sarepta Therapeutics' SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of $1.36 billion and a stock th... Full story

Yahoo Finance • 4 months ago

REGENXBIO Inc. (RGNX): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish the... Full story

Yahoo Finance • 5 months ago

REGENXBIO's gene therapy with CT domain shows improved muscle function in study

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX), a biotechnology company whose stock has gained over 22% in the past six months and is currently considered undervalued according to InvestingPro analysis, published preclinical research Thursd... Full story

Yahoo Finance • 5 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid challenges

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company focused on developing gene therapies for rare diseases, has garnered significant attention from investors and analysts alike. The company’s lead candidate, SGT-003, for the tre... Full story

Yahoo Finance • 6 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid DMD competition

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $350 million focused on developing gene therapies for rare diseases, has been making significant strides in its pursuit of treatments for Duchen... Full story

Yahoo Finance • 7 months ago

Q1 2025 Regenxbio Inc Earnings Call

Participants Patrick Christmas; Chief Legal Officer; Regenxbio Inc Curran Simpson; President, Chief Executive Officer and Board Member; Regenxbio Inc Stephen Pakola; Executive Vice President, Chief Medical Officer; Regenxbio Inc Mitche... Full story

Yahoo Finance • 2 years ago

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the t... Full story

Yahoo Finance • 2 years ago

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

Kenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing. Regenxbio Inc is a biotechnology company focused on the development, c... Full story

Yahoo Finance • 2 years ago

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to RE... Full story

Yahoo Finance • 2 years ago

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Highest priority programs are ABBV-RGX-314 for the... Full story